EDMONTON, Alberta — October 31, 2012. Fedora Pharmaceuticals, Inc. announced the creation of a Board of Directors and the appointment of Leonard E. Post, Ph.D. and Ronald W. Odynski, Q.C. as directors. The Board is chaired by Christopher Micetich, CEO and founder.
Len and Ron have an impressive combined expertise in the legal, corporate governance, drug development, regulatory, and commercialization aspects of the biotechnology industry. These skills will be particularly valuable as Fedora aims to secure the most advantageous partnerships in the development of our β-lactamase inhibitor program.Christopher Micetich, CEO & Founder
Ronald Odynski is managing partner of Ogilvie LLP, providing general counsel and corporate governance advice. He served as general legal counsel and a founding board member at Synphar Laboratories Inc., the biopharmaceutical company founded by the late Dr. Ronald Micetich.
Dr. Leonard E. Post has over 30 years of experience across pharmaceutical and biotech R&D, from early discovery through FDA approval. He was chief scientific officer of BioMarin Pharmaceuticals and held senior positions at LEAD Therapeutics, Onyx Pharmaceuticals, and Parke-Davis.
About Fedora Pharmaceuticals
Fedora Pharmaceuticals Inc. is an innovative biotech founded in 2011 and headquartered in Edmonton, Alberta, Canada. The company is dedicated to discovering and developing novel antimicrobial drugs to tackle antibiotic resistance (AMR). Fedora’s most advanced candidate is nacubactam, a Phase 3-ready β-lactamase inhibitor being advanced with partner Meiji Seika; Fedora holds key US rights to nacubactam. For more information, visit fedorapharma.com.
